These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 16965601)

  • 1. Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer.
    Araki K; Fujita K; Ando Y; Nagashima F; Yamamoto W; Endo H; Miya T; Kodama K; Narabayashi M; Sasaki Y
    Cancer Sci; 2006 Nov; 97(11):1255-9. PubMed ID: 16965601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan.
    Ando Y; Ueoka H; Sugiyama T; Ichiki M; Shimokata K; Hasegawa Y
    Ther Drug Monit; 2002 Feb; 24(1):111-6. PubMed ID: 11805731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.
    Ando Y; Saka H; Ando M; Sawa T; Muro K; Ueoka H; Yokoyama A; Saitoh S; Shimokata K; Hasegawa Y
    Cancer Res; 2000 Dec; 60(24):6921-6. PubMed ID: 11156391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of UGT1A9 intronic I399C>T polymorphism on SN-38 glucuronidation in Asian cancer patients.
    Sandanaraj E; Jada SR; Shu X; Lim R; Lee SC; Zhou Q; Zhou S; Goh BC; Chowbay B
    Pharmacogenomics J; 2008 Jun; 8(3):174-85. PubMed ID: 17700594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The UGT1A1*28 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation.
    Liu Y; Ramírez J; House L; Ratain MJ
    Eur J Cancer; 2010 Jul; 46(11):2097-103. PubMed ID: 20580994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil.
    Wang Y; Shen L; Xu N; Wang JW; Jiao SC; Liu ZY; Xu JM
    World J Gastroenterol; 2012 Dec; 18(45):6635-44. PubMed ID: 23236239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of one-point plasma SN-38G/SN-38 concentration ratios as a substitute for UGT1A1 genetic information after irinotecan administration.
    Hirose K; Yamashita K; Takada H; Kaneda N; Fukami K; Maruo E; Kitamura M; Hasegawa J; Maeda Y
    Int J Clin Oncol; 2014 Apr; 19(2):397-402. PubMed ID: 23605141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan.
    Nagar S; Blanchard RL
    Drug Metab Rev; 2006; 38(3):393-409. PubMed ID: 16877259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irinotecan treatment in cancer patients with UGT1A1 polymorphisms.
    Innocenti F; Ratain MJ
    Oncology (Williston Park); 2003 May; 17(5 Suppl 5):52-5. PubMed ID: 12800608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38.
    Paoluzzi L; Singh AS; Price DK; Danesi R; Mathijssen RH; Verweij J; Figg WD; Sparreboom A
    J Clin Pharmacol; 2004 Aug; 44(8):854-60. PubMed ID: 15286088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.
    Iyer L; Das S; Janisch L; Wen M; Ramírez J; Karrison T; Fleming GF; Vokes EE; Schilsky RL; Ratain MJ
    Pharmacogenomics J; 2002; 2(1):43-7. PubMed ID: 11990381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan.
    Stewart CF; Panetta JC; O'Shaughnessy MA; Throm SL; Fraga CH; Owens T; Liu T; Billups C; Rodriguez-Galindo C; Gajjar A; Furman WL; McGregor LM
    J Clin Oncol; 2007 Jun; 25(18):2594-600. PubMed ID: 17577039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights, challenges, and future directions in irinogenetics.
    Kim TW; Innocenti F
    Ther Drug Monit; 2007 Jun; 29(3):265-70. PubMed ID: 17529881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene Polymorphisms.
    Yokokawa A; Kaneko S; Endo S; Minowa Y; Ayukawa H; Hirano R; Nagashima F; Naruge D; Okano N; Kobayashi T; Kawai K; Furuse J; Furuta T; Shibasaki H
    Eur J Drug Metab Pharmacokinet; 2021 Mar; 46(2):317-324. PubMed ID: 33619631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28.
    Minami H; Sai K; Saeki M; Saito Y; Ozawa S; Suzuki K; Kaniwa N; Sawada J; Hamaguchi T; Yamamoto N; Shirao K; Yamada Y; Ohmatsu H; Kubota K; Yoshida T; Ohtsu A; Saijo N
    Pharmacogenet Genomics; 2007 Jul; 17(7):497-504. PubMed ID: 17558305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer.
    Marcuello E; Altés A; Menoyo A; Del Rio E; Gómez-Pardo M; Baiget M
    Br J Cancer; 2004 Aug; 91(4):678-82. PubMed ID: 15280927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetic pathway analysis of irinotecan.
    Rosner GL; Panetta JC; Innocenti F; Ratain MJ
    Clin Pharmacol Ther; 2008 Sep; 84(3):393-402. PubMed ID: 18418374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism.
    Iyer L; Hall D; Das S; Mortell MA; Ramírez J; Kim S; Di Rienzo A; Ratain MJ
    Clin Pharmacol Ther; 1999 May; 65(5):576-82. PubMed ID: 10340924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [UGT1A1 Genotyping for Proper Use of Irinotecan].
    Matsuoka A; Ando Y
    Rinsho Byori; 2015 Jul; 63(7):876-82. PubMed ID: 26591441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene and irinotecan toxicity.
    Kitagawa C; Ando M; Ando Y; Sekido Y; Wakai K; Imaizumi K; Shimokata K; Hasegawa Y
    Pharmacogenet Genomics; 2005 Jan; 15(1):35-41. PubMed ID: 15864124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.